OFF-LABEL USE OF ANTIBACTERIALS IN A CONTEXT OF ANTIMICROBIAL RESISTANCE THREAT by GISELE S LEMOS et al.
Vol 12, Issue 6, 2019
Online - 2455-3891 
Print - 0974-2441
OFF-LABEL USE OF ANTIBACTERIALS IN A CONTEXT OF ANTIMICROBIAL RESISTANCE 
THREAT
Received: 18 March 2019, Revised and Accepted: 19 April 2019
ABSTRACT
Objective: The objective of the study was to describe the off-label use of antibacterial in prescriptions for hospitalized adult patients as per the 
Brazilian drug regulatory agency, namely, the National Health Surveillance Agency (ANVISA).
Methods: This is a cross-sectional study with prescriptions for inpatients in a teaching hospital. Data collection and analysis were based on the 
checklist of the Medicine Prescription, Use and Administration Protocol of the Ministry of Health, where the off-label use is classified as per information 
of ANVISA’s Electronic Bulletin. Descriptive analyses were performed, and the method of logistic regression was used to evaluate the association 
between the off-label use of antibacterial and the explanatory variables age, gender, hospitalization clinic, and medical specialty.
Results: About one-third of the antibacterial was prescribed for off-label use, and the frequency of administration was the primary use outside 
standards established in the products’ licenses (87.3%), and dose (7.4%) and the administration route was next. The third-generation cephalosporin 
was the most consumed class in this regimen (69.5%). In some cases, the off-label use was not supported by scientific evidence. The off-label use was 
positively associated with the variables gender (odds ratio [OR] = 2.48; confidence interval [CI] = 1.23–4.92) and the prescribing clinic (OR = 4.94; 
CI = 2.61–8.96).
Conclusion: Off-label use is a frequent practice in the studied environment, and in the face of a dramatic scenario of increased antibacterial resistance, 
it is imperative to adopt measures for the standardization of records and the rational use of this class of drugs.
Keywords: Drug prescriptions, Anti-infective agents, Drug use, Patient safety, Off-label use, Hospitals.
INTRODUCTION
One of the global challenges in the area of health is antimicrobial 
resistance, and it is urgent to rethink the use of antimicrobial drugs 
(AMD). The higher frequency of microbial resistance threatens 
the return of a time when infections were inevitably deadly or 
disabling, compromising treatments, and prevention in surgical and 
chemotherapy procedures. This raises the need to promote strategies 
to increase awareness and knowledge of the subject and foster safe and 
appropriate AMD use [1,2]. This is especially noticeable in hospitals 
where they are the second most used drug class and are responsible for 
the high drug costs [3].
The use of clinical and epidemiological methods to analyze the potential 
benefits and risks of drug therapy has become a requirement for the 
rational use of drugs. The knowledge of how drugs are being prescribed 
is necessary to suggest measures to improve prescribing habits, and 
the scientific evidence-based practice seeks to ensure drug safety, 
efficacy, and effectiveness [1-4]. The introduction of an antimicrobial 
stewardship program is required to improve the rational use of AMD, 
besides guidelines and an antimicrobial use monitoring process [4,5].
Off-label use is the term utilized for the use of a drug other than that 
recommended and listed in the product registration and package 
insert. It is associated with the freedom of evaluation and decision of 
the prescriber and is not illegal or necessarily incorrect [1]. Prescribing 
AMD is a common practice both in outpatient and inpatient care [6, 7]. 
High rates of off-label use of these drugs in adult (19% to 43%) and 
pediatric (1% to 94%) patients have been reported [8]. Decision-making 
for this type of use must be guided by safe and evidence-based criteria, 
ensuring adequate drug therapy. It involves, among other factors, 
indication, dose, administration route, frequency of administration, 
duration of treatment, lack of contraindications, and minimum 
likelihood of adverse reactions.
Further studies are required on this thematic to encourage the ethical 
use of off-label drugs. The checklist of the Brazilian Medication 
Prescription, Use and Administration Safety Protocol of the Ministry 
of Health is a document based on well-established scientific 
evidence and is a reliable source evaluating prescriptions in drug use 
studies [9]. Based on this instrument, we aimed to analyze the practice 
of prescriptions off-label AMDs in a public teaching hospital. The study 
bridges a gap in literature describing the off-label use of antibacterial 
in prescriptions for hospitalized adult patients as per the Brazilian 
drug regulatory agency, namely, the National Health Surveillance 
Agency (ANVISA).
METHODS
Study design and setting
This is a cross-sectional study carried out in a public hospital that 
provides care exclusively through the Unified Health System (SUS) 
and locates in the Northeast of Brazil. The hospital provides teaching, 
research, and related activities for undergraduate and graduate 
students. It is the reference hospital for the care of approximately 
600,000 inhabitants in 26 cities of the South Regional Health Center, with 
a 180-bed urgency and emergency capacity, internal medicine, surgical 
and orthopedic clinic, pediatrics, psychiatry, neurology, and intensive 
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care unit (ICU). Antimicrobial stewardship was not implemented in the 
hospital. Clinical pathways published by the Hospital Infection Control 
Committee are not available frequently. Thus, AMDs are prescribed 
empirically and sometimes without microbial culture or gram. The 
hospital prescription is performed by a computerized physician order 
entry. The inpatient drug distribution system is individualized up to 
24 h.
Sample
Individual prescriptions of patients of all ages with a hospital stay of 
more than 24 h in the period July 1–31, 2016, were included in this 
study. AMDs were chosen as markers because they were among the 
most prescribed drugs used in hospitals [4]. Prescriptions kept at the 
hospital pharmacy after drug dispensing was used as sample units, and 
the antimicrobials were the unit of analysis.
Inclusion criteria were individualized prescriptions of inpatients 
containing at least one drug on the hospital standardization list issued 
during the time of the survey as per the sampling process. Exclusion 
criteria were prescriptions of non-hospitalized patients attended in the 
emergency and outpatient services, and prescriptions without drug 
therapy. Prescriptions from Internal Medicine, surgical and orthopedic 
clinic, Neurology and the ICU were included. The other clinics were 
excluded because they did not issue individualized prescriptions 
(adopting a bulk ward stock), due to operational difficulties and 
technical access to medical records or because they did not have an 
inpatient service, respectively.
Data collection, instrument, and variables
For the collection, we used a form based on the checklist of the 
Medication Prescription, Use and Administration Safety Protocol [9].
The off-label use of AMDs was considered the outcome, characterized as 
any information discrepancy between the prescription and the product’s 
package insert. We considered in this study the off-label use of “dose,” 
“administration route,” “administration frequency,” and “age” (higher 
or lower than prescribed doses, administration frequency other than 
those recommended, administration routes that are in disagreement 
with those indicated and drugs prescribed for ages different from those 
recommended) [10]. The off-label use was classified as per the product 
license information contained in the professional’s leaflet of ANVISA’s 
Electronic Bulletin, the authority responsible for the regulation of 
medicines in Brazil [11]. The indication of use was not taken into 
consideration since all the prescriptions of AMD were administered 
immediately, timely, and empirically because the hospital did not have 
clinical protocols for AMD use, did not perform microbiological culture 
or gram. The independent variables were age (categorized from 0 to 18 
years, from 19 to 59 years, and 60 years and over), gender, inpatient 
clinic, and medical specialty.
The patient’s sociodemographic and clinical variations were 
collected from the medical records and the antimicrobials’ data in the 
prescription.
The ATB were classified as per the first and fourth level of the 
Anatomical Therapeutic Chemical Classification (ATC) of the World 
Health Organization (WHO) in 15 pharmacological groups (fourth 
level). The evaluation of the off-label use of dose and frequency 
of administration (dose adjustment in geriatrics or patients with 
hepatic or renal function impairment) was performed by searching 
in laboratory tests (tests of creatinine, prothrombin time, albumin, 
and bilirubin) and clinical evaluation notes the diagnosis for renal or 
hepatic impairment. The Cockcroft-Gault formula was used to evaluate 
the need for renal adjustment.
Data analysis
A descriptive analysis was performed by estimating the absolute and 
relative frequencies of the selected variables. The continuous variables 
were shown through means and standard deviation. The Pearson’s Chi-
square test was used to compare proportions of categorical variables.
The association between the off-label use and the selected independent 
variables was performed through univariate and multivariate analyses 
using the binary logistic regression model. The magnitude of the 
association was calculated using odds ratios (ORs) with 95% confidence 
intervals (CI) and a significance level of 0.05. The independent effect of 
the variables on off-label use was verified in the multivariate analysis. 
The strategy of constructing the models was carried out by deleting 
variables until the final model was obtained, in which those with p < 0.05 
remained. The Hosmer-Lemeshow test was used to verify the suitability 
of the final model. EpiData 3.1, 2008 (EpiData Association, Odense, 
Denmark) and SPSS 21.0, 2016 (IBM Corporation, Armonk, United 
States, USA) were used for tabulation and data analysis, respectively.
Ethical considerations
The study was approved by the Research Ethics Committee of the Federal 
University of Minas Gerais (UFMG) under CAAE 1.325.634/2015.
RESULTS
Of the 352 prescriptions, 59.0% (n = 211) contained AMDs. In total, 289 
antimicrobial agents were prescribed containing 18 different drugs. 
Prescriptions had one (66.8%), two (29.4%) or three (3.8%) AMDs, but 
not all of them could be evaluated for off-label use, and 4.5% (13) did 
not contain information on dose, frequency, or administration route. Of 
the prescribed AMDs, 93 (33.6%) had discrepancies with the registry 
at ANVISA, and two prescriptions had two off-label types, totaling 95 
(Table 1).
AMDs were classified according to the ATC classes, in which the five 
most prescribed classes were third-generation cephalosporins (28.1%), 
fluoroquinolones (23.6%), lincosamides (12.1%), fourth-generation 
Table 1: Demographic and pharmacotherapeutic characteristics 
of antimicrobial prescription of patients hospitalized in a public 
teaching hospital (n=211)
Clinic, n (%)
Internal medicine 70 (33.2)











Number of prescription 352
Number of antimicrobial prescription 211
Number of antimicrobial drugs 289
Number of antimicrobial prescriptions off-label as 
per ANVISA
93
Number of off-label prescribed 95
ICU: Intensive care unit, ANVISA: National Health Surveillance Agency
The sample was calculated using the StatCalc tool from Epi 
Info  software  7.0,  considering  a  5%  alpha  error,  a  10%  beta  error, 
and the mean prescriptions containing AMDs in the month before
 the  start  of  the  collection,  resulting  in  340  prescriptions. 
Hospital  pharmacy  prescriptions  were  sequentially 
numbered,and  sampling  was  performed  as  per  the 
traditionalsystematic  sampling  criteria,  with  a  prospect  of  15 
daily  prescriptions and a  sampling interval  of  six.  Considering 
thedecision  to  sample  all  the  prescriptions  issued  in  a  given 
month,  namely,  July  2016,  the  process  was  continued  even  after 
reaching the calculated value, raising the sample to 352 prescriptions.
Characteristics
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cephalosporin (9%), carbapenems (7.6%), and others (19.6%). Table 2 
shows the frequency of AMD used in the off-label regime, as per the ATC 
classification. The off-label use of “administration frequency” had the 
highest occurrence (87.3%), 95.2% toward increase and 4.8% toward 
decrease in the frequency. Third-generation cephalosporin ceftriaxone 
accounted for 78.4% of this discrepancy, all involving a two- to four-
fold increase compared to the recommended frequency. Metronidazole, 
cefepime, and meropenem for parenteral use had up to four-fold daily 
increase in the frequency of administration, and ampicillin a six-fold 
daily increase.
Off-label use of “administration route” and “dose” appeared with 
frequencies of 5.3% and 7.4%, respectively. In the case of the 
“administration route,” all involved the administration through a 
nasoenteral or gastric probe; while in the case of “dose,” 57.1% was 
related to sub dose and 42.9%, overdose. The dose discrepancies 
involved vancomycin doses of 500 or 2000 mg every 12 h and 
levofloxacin 500 mg at 12-h intervals. No age use off-label was found.
The classes of AMDs prescribed in off-label regimen varied with the 
medical specialty and the hospitalization clinic, and the surgical and 
orthopedic clinic was the most frequent location of the event (63.4%). 
The general practitioner (university graduate) was the one that most 
prescribed AMDs for off-label use (38.5%) (Table 3).
The mean age of patients with off-label AMD prescriptions was 45.9 
± 22.6 years (13–91 years), and third-generation cephalosporin was 
the most used class in off-label regimen in all age groups. The age 
range of 19–59 years and males was the most involved in off-label use 
(57.0% and 72.0%, respectively). Eight prescriptions contained two 
classes of AMDs associated in an off-label regime (carbapenems and 
glycopeptides used in a higher frequency of association).
In the univariate analysis, the medical specialty and the prescribing clinic 
were associated with off-label use. On the other hand, the prescribing 
clinic was independently associated with off-label use (Table 4).
DISCUSSION
Our findings confirm that despite all the problems involving 
antimicrobial agents, these are still prescribed off-label and allow us to 
show that this practice was adopted in about one-third of prescriptions 
containing AMD. These findings sensitize us about the higher risk of 
adverse events associated with this prescription profile, considering 
that off-label drug’s efficacy/effectiveness and safety are not (generally) 
adequately assessed. The current scenario of AMD use worldwide has 
shown increasing levels of microbial resistance, and declining discovery 
of novel AMD drugs. Therefore, the off-label use of AMD is of great 
concern and should be further investigated [12,13].
The unit where the study was performed is a teaching hospital linked 
to the SUS, but until then, it had not implemented policies to control the 
prescribed drugs. There were no AMD use protocols and microbiological 
cultures were interrupted due to contractual and bidding problems 
with the outsourced provision of this service. This is very relevant if 
we consider the professional training process developed there and the 
consolidation of government policy to promote patient safety and the 
threat of bacterial resistance.
Most patients received a monotherapy treatment, in line with the main 
recommendations for the rational use of AMD [14]. The prevalence of 
males in the general and off-label consumption of AMD is a probable 
consequence of the higher number of hospitalizations due to accidents, 
mainly road traffic injuries, and other external causes prevalent in 
Brazil [15]. Since the Ministry of Health classifies it as medium-and 
high-complexity traumatology and orthopedics care unit, the hospital 
plays a key role as a referral to provide care to these cases in the region. 
Most of those involved in these accidents are middle-aged, which 
explains the higher consumption of AMD in the 19–59 years’ age group.
While high, the frequency found by us underestimates the reality of this 
practice, since we did not evaluate the off-label use of AMD indication. 
The frequency was lower than that found in another university 
Table 2: Frequency distribution of the off‑label use of antimicrobial drugs as per the anatomical therapeutic chemical classification (n=95)
ATC code Class Off‑label use (%)
AF (n=83) Dose (n=7) Administration route (n=5)
J01DD Third-generation cephalosporins (ceftriaxone) 78.4 - -
J01DE Fourth-generation cephalosporins (cefepime) 6.0 - -
J01XA Glycopeptide anti-bacterial (vancomycin) - 80.0 -
J01MA Fluoroquinolones (ciprofloxacin, levofloxacin) 2.4 20.0 80.0
J01DH Carbapenems (meropenem) 4.8 - -
S01AA Eye antibiotics (tobramycin) 4.8 - -
J01XD Imidazole derivative (metronidazole) 2.4 - 20.0
J01CA Penicillins, extended-spectrum (ampicillin sodium) 1.2 - -
Total 100.0 100.0 100.0
ATC: Anatomical therapeutic chemical, AF: Administration frequency
Table 3: Frequency distribution of the off‑label use of antimicrobial prescription as per the prescribing clinic and medical specialty
Yes (%) No (%)
Clinic (n=93)
Internal medicine (n=82) 22.0 78.0 <0.001
Surgical and orthopedic surgery (n=111) 53.2 46.8
Neurology (n=31) 25.8 74.2
ICU (n=52) 15.4 84.6
Medical specialty (n=91)
Others* (n=85) 29.4 70.6 0.003
General surgeon (n=80) 23.8 76.3
General practitioner (university graduate) (n=77) 45.5 54.5
Orthopedist (n=23) 52.2 47.8
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hospital [1], although similar to that found in the ICU [16]. Third-
generation cephalosporins, the most prescribed antimicrobial agents, 
for off-label use as well, and the most consumed in all age groups, 
have low relative toxicity and extended spectrum [1-4]. This may be 
due to difficulties in determining the etiology of infection through the 
current hospital conditions, and by the lack of standardization in the 
decision-making for a prescription. These conditions lead to greater 
difficulties in acquiring knowledge about ADMs and the presence of 
multi-resistant strains [17]. Thus, the off-label use of this class of 
drugs is safer to the prescriber.
The practice of off-label use may be supported in situations where the 
drug has already shown to be useful in non-approved regimens, mainly 
if some scientific evidence includes at least one randomized controlled 
trial (RCT) [17], even without changes to the registry. Studies suggest 
that the prescription of a drug is not based only on what is recommended 
in the package insert, but one should take into account whether or not 
alternative treatments exist, the severity of the clinical condition and 
the lack of records due to market reasons [18]. We analyzed 13 different 
regimens prescribed in off-label use as per ANVISA, and when compared 
to the Food and Drug Administration (FDA) [19], we found ten off-
label regimens, that is, the labels registered in regulatory agencies, 
sometimes by the same manufacturer, are different, thus reinforcing 
the need to consider such a reality in future drug registration decisions.
The most prevalent off-label use refers to changes in the frequency of 
administration. Such changes, when not performed safely and based 
on scientific evidence, may harm patient care [1,19]. For example, 
ceftriaxone powder for injectable solution, namely, the primary drug 
involved with this type of off-label use, was prescribed at 12-h intervals 
or even every 6 h instead of every 24 h, but the daily dose of 2 g was 
maintained. Ceftriaxone is among the time-dependent antibiotics due 
to its long half-life time and high plasma protein binding, assuring 
a serum concentration between 60% and 70% above the minimum 
inhibitory concentration between doses [20]. Although in this 
study we do not have the possibility of a clinical trial for use outside 
established standards, and while pharmacokinetics, in this case, favor 
a 24-h dosing schedule, there is scientific evidence that, for critically 
ill patients, ceftriaxone dose is indicated to be fractionated at 12-h 
intervals [21,22], which is a clinical prerogative for the prescriber’s 
decision. The registration in the regulatory agencies of the U. S. and the 
European Union is permissive with the administration regimen at every 
12 h, although with reservations (the European Medicines Agency 
records the dosage indication at the maximum dose of 4 g/day) [23,24]. 
These data suggest the outdated registration of ANVISA and reaffirm 
the need to update this document by manufacturers and review the 
product license at this regulatory agency. Thus, the Brazilian package 
insert could also be adapted and RCT could be conducted to compare 
ceftriaxone administration, the full dose administered once or full dose 
divided into two daily administrations.
Pharmacokinetic and pharmacodynamic parameters must be 
evaluated before any change in the frequency of administration or 
the dose of medicines. For example, for concentration-dependent 
AMDs, such as levofloxacin, as an injectable solution, a single dose 
per day is recommended, which achieves maximum concentrations 
at the site of infection, thus producing the maximum bactericidal 
effect [20]. However, we found in this study that it was prescribed 
twice a day, maintaining the usual dose of 500 mg, which disregards 
the pharmacokinetic and pharmacodynamic profile of the drug, 
impairing safety, and generating possible additional costs. It has been 
documented in literature that fluoroquinolones, including levofloxacin, 
are associated with increased risk of tendinitis, tendon rupture, cardiac 
arrhythmia, renal injury, and retinal detachment [7]. Thus, if there is no 
evidence to ensure the change in administration or dose intervals, the 
guidelines recommended in the package insert should be maintained. 
Therefore, our primary challenge is to maintain the effectiveness of the 
available AMDs, using them as per their individual pharmacokinetic 
and pharmacodynamic characteristics [14].
Regarding the off-label use of the “administration route,” it was 
associated with a change in the administration of coated tablets through 
a nasogastric or nasoenteral tube. The recommendations in the package 
insert instructions are clear of not breaking, opening, or chewing such 
tablets. The prescription of this route can be considered a prescription 
error leading to a possible administration error. The preventable 
adverse events are a worldwide concern; one of the five leading causes 
of death [25] and nonoptimized drug therapy are responsible for costs 
of around 500 billion per year [26]. Another critical issue is that the 
manufacturer provides the pharmaceutical form of levofloxacin oral 
solution registered at the FDA [19], but not in Brazil, which is the most 
indicated pharmaceutical form for use in a probe.
Vancomycin was also involved in the off-label use of the dose. In this 
study, the dose of vancomycin was considered as off-label, since the 
package insert registered at ANVISA is incomplete, without the option of 
a dose per mg/kg of weight for adult or elderly patients with normal renal 
function. Another relevant measure would be the elaboration of clinical 
protocols by the hospital institution since the quality of drug therapy 
is not necessarily associated with the product registration status [10]. 
Vancomycin was also involved in the association with meropenem, both 
in an off-label regimen, and this association is the most recurrent. Patients 
who receive an overdose of vancomycin or in an off-label combination 
were at a higher risk of adverse reactions since vancomycin is among the 
main responsible for interactions and risks of nephrotoxicity [27].
Table 4: Multiple logistic regression for off‑label use with explanatory variables included in the model: Age, gender, medical specialty 
and prescribing clinic (n=95)
Explanatory variable Off‑label use (%) Univariate analysis Multivariate analysis
OR (CI) p* OR (CI) p*
Age
0–59 years 69.9 1.0 0.076
60 years and over 30.1 1.62 (0.96–2.77)
Gender
Male 72.0 1.39 (0.78–2.46) 0.263
Female 28.0 1.0
Medical specialty
Medical specialists** 61.5 1.96 (1.14–3.39) 0.016
General practitioner (university graduate) 38.5 1.0
Clinic
ICU + internal medicine + neurology 36.6 1.0 <0.001 1.0 <0.001
Surgical and orthopedic 63.4 4.37 (2.57–7.43) 4.20 (2.28–7.72)
Hosmer–Lemeshow test 0.962
*Binary logistic regression, statistically significant p value (<0.05), CI=95%, **Medical specialists: Neurologist, gastroenterologist, nephrologist, dermatologist, 
neurologist, maxillofacial, cardiologist, general surgeon, orthopedist. ICU: Intensive care unit, CI: Confidence interval, OR: Odds ratio
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In a prospective cohort [17], it has been found that adverse drug events 
are more frequent in situations where the use is not based on scientific 
evidence. Our data allow us to emphasize that use without this evidence is 
not uncommon, and AMD use control policies (antimicrobial stewardship 
program) must be formulated and conducted by specialists, including 
physicians, pharmacists, microbiologists, and nurses [4,5]. Pharmacists 
play a key role in drug use studies due to their expertise in the area of 
pharmaceutical care, such as minimizing toxicity and other adverse events, 
reducing the costs of health care for infections, limiting the selection of 
antimicrobial resistant strains and ensuring patient safety [4,28].
The off-label use was more frequently associated with males and 
the surgical and orthopedic clinic as a location of hospitalization. 
In Brazil, surgical site infections comprised 14%–16% of infections 
in hospitalized patients and are the second or third most frequent 
infection among all infections in health-care services [29,30], and the 
hospital is a reference in urgency and emergency and is accredited by 
the Ministry of Health for High Complexity Services in Traumatology 
and Orthopedics. Due to the experimental use, the prevalence of off-
label prescription of extended-spectrum antimicrobials could be a 
reasonable indication for this association.
The cross-sectional design of our study prevented us from ascertaining 
the International Classification of Diseases (if available) related to AMDs 
prescription and, therefore, the off-label indication use of AMDs could 
not be analyzed. Furthermore, as a limitation is a fact that the study was 
performed in only one hospital. Notwithstanding this, we believe that the 
study contributed significantly by showing that off-label use is common 
practice (even) in a teaching hospital. In the face of a dramatic setting 
of increased antibacterial resistance associated with few novel AMD 
registries [3,4,12,17], there is the need to plan prescription monitoring 
actions, encompassing the implantation of a microbiology laboratory to 
support therapeutic decisions, inclusion of AMD prescription protocols, 
drug restriction, continuing education, and pharmacotherapeutic follow-
up by specialized professional, pharmacists [4,5,31]. Considering that 
the studied hospital is an educational institution, this need is even more 
relevant because elaborating better quality prescriptions is an example 
of the training of new professionals, not only physicians but also the 
whole team. It is also worth noting that a permissive environment for 
lower risk errors will also be an environment in which the risk of serious 
errors can occur more easily. Finally, the pharmaceutical industry often 
proceeds against this rationality, registering package inserts that can 
be different dosing profiles for the AMDs. Since the package insert is a 
public document with up-to-date information on efficacy, effectiveness, 
safety, and also studies on pharmacoeconomics, the regulatory agencies 
should act more rigorously in the analysis of marketed products and 
their information.
CONCLUSION
Off-label prescription is a reality in the hospital studied and is found in 
about one-third of prescriptions containing AMD. In several occasions, 
it occurred with no scientific evidence to support it. The creation of 
mechanisms that regulate the AMD use, especially in off-label regimen 
should be adopted in our hospitals, so that the use of these medicines is 
done rationally, providing the patient with the effectiveness and safety 
of drug therapy so as to contribute to the new strategic plan of the WHO 
– 13th General Program of Work – which will last 5 years.
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